The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Abstract The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to imp...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2022-05-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44228-022-00007-5 |